SPONSOR

AbbVie

Total Trials

Recruiting

Phases

Phase 3, Phase 2, Phase 3, Phase 1, Phase 2

Conditions studied: Ulcerative Colitis Migraine Diabetic Retinopathy Hepatocellular Carcinoma (HCC)Healthy Volunteer Hepatocellular Carcinoma Systemic Lupus Erythematosus Rheumatoid Arthritis Advanced Squamous Tumors Hypothyroidism

AbbVie is a US-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. The company built its early commercial foundation on adalimumab (Humira), which became the world's best-selling drug for over a decade, treating rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, and other immune-mediated conditions. AbbVie's clinical research now spans immunology, oncology/hematology, aesthetics, neuroscience, and eye care — driven significantly by the 2020 acquisition of Allergan.

In hematology, AbbVie's venetoclax (Venclexta) — a BCL-2 inhibitor developed with Genentech/Roche — has established itself as a cornerstone therapy in chronic lymphocytic leukemia and acute myeloid leukemia, with ongoing trials exploring combinations with targeted agents, CAR-T cells, and bispecific antibodies. The immunology pipeline post-Humira biosimilar era is focused on next-generation IL-23 inhibitors (risankizumab/Skyrizi) and JAK inhibitors (upadacitinib/Rinvoq), both of which are in Phase 3 trials across new indications including giant cell arteritis and uveitis.

AbbVie's neuroscience program includes significant investment in migraine prevention (atogepant, ubrogepant) and Parkinson's disease (levodopa-carbidopa intestinal gel continuous infusion). The aesthetics division, inherited from Allergan, runs trials on neurotoxins and dermal fillers, representing a distinct category of interventional research. AbbVie conducts trials at academic and clinical research sites globally and maintains an open innovation model through partnerships with smaller biotechs.

Frequently Asked Questions — AbbVie

What is venetoclax and for which blood cancers is AbbVie testing it?

Venetoclax (Venclexta) is a first-in-class BCL-2 inhibitor that restores programmed cell death in cancer cells that have become resistant to apoptosis. It is FDA-approved in combination with rituximab for relapsed/refractory CLL, with obinutuzumab for previously untreated CLL/SLL, and with azacitidine or decitabine for newly diagnosed AML in patients 75 years or older who cannot tolerate intensive chemotherapy. AbbVie and Genentech are jointly running Phase 3 trials testing venetoclax in additional combinations — including with ibrutinib, acalabrutinib, and CAR-T therapies — and exploring its role in other hematologic malignancies including follicular lymphoma and mantle cell lymphoma.

What immunology conditions does AbbVie study beyond rheumatoid arthritis?

AbbVie's current immunology trials extend well beyond RA. Risankizumab (Skyrizi), an IL-23p19 inhibitor, is approved and under active study in plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, with trials now expanding to ankylosing spondylitis and other spondyloarthropathies. Upadacitinib (Rinvoq), a selective JAK1 inhibitor, is approved in RA, atopic dermatitis, PsA, AS, non-radiographic axSpA, and Crohn's, with Phase 3 trials in giant cell arteritis, uveitis, and systemic lupus underway. AbbVie also has early-stage programs in systemic sclerosis and alopecia areata.

How has the Allergan acquisition changed AbbVie's clinical trial activity?

The 2020 Allergan acquisition significantly diversified AbbVie's trial portfolio beyond immunology and oncology. Allergan brought approved products in eye care (dry eye disease treatments), central nervous system (buprenorphine, muscle relaxants), aesthetics (onabotulinumtoxinA/Botox, Juvederm fillers), and women's health. Post-acquisition, AbbVie runs trials extending Botox indications (including bladder dysfunction, chronic migraine, limb spasticity), investigational eye disease therapies, and next-generation aesthetic biologics. The neuroscience portfolio now also includes CGRP receptor antagonists for migraine (atogepant) and opioid dependence programs.

AbbVie

Frequently Asked Questions — AbbVie

Clinical Trials by AbbVie

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy

A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants

A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants

An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder